Is sdLDL a valuable screening tool for cardiovascular disease in patients with metabolic syndrome?
| Autor: | Ola A. Akl, Radwa Momtaz Abdelsamie Zaki Khalil, Dalia Ahmed Mohamed Al-Azab |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Very low-density lipoprotein
medicine.medical_specialty lcsh:Medicine 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Bioinformatics 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine High-density lipoprotein Internal medicine Medicine Small dense low density lipoprotein Metabolic syndrome Cardiovascular disease Prevention Atherogenic Screening business.industry Prevention lcsh:R Atherogenic General Medicine Small dense low density lipoprotein Cardiovascular disease Vertical auto profile medicine.disease Metabolic syndrome Endocrinology chemistry Intima-media thickness Low-density lipoprotein Screening lipids (amino acids peptides and proteins) Density gradient ultracentrifugation business Lipoprotein |
| Zdroj: | Alexandria Journal of Medicine; Vol 53, No 4 (2017); 299-305 Alexandria Journal of Medicine, Vol 53, Iss 4, Pp 299-305 (2017) |
| ISSN: | 2090-5076 2090-5068 2090-2948 1110-0834 |
| Popis: | Many patients with cardiovascular disease have their low density lipoprotein cholesterol within normal range. This raises the question about the most important lipoprotein to use as a marker of atherogenecity. In fact, small dense low density lipoprotein has recently been suggested as a strong predictor of cardiovascular disease. Among high risk patients, those with metabolic syndrome represent an important target population. Different methods of small dense low density lipoprotein measurement were developed. Accordingly, two phenotypes of low density lipoprotein are recognized: Phenotype A (predominance of large buoyant low density lipoprotein) & phenotype B (predominance of small dense low density lipoprotein). However, none of the methods has been yet considered as a gold standard one. A lot of studies confirmed the role of small dense low density lipoprotein in the development of cardiovascular disease through atherogenic properties & clinical trials. However, others failed to do so. These discrepancies may be due to different sample sizes, different populations, different age groups, different methods of measurement & other possible confounding factors. The aim of this review is to discuss the role of small dense low density lipoprotein as a valuable screening/ preventive tool of cardiovascular disease in patients with metabolic syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|